{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/65389962df30c3001242ec3b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"71. ESMO 2023 - Early Breast Cancer (Part 1)","description":"<p>Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug their shoulders and say \"why don't we do all of them.\" ESMO 2023 is one such instance. Despite their best efforts, our intrepid duo were unable to narrow down their presentation of early breast cancer highlights to one episode, so they are going to do two (for the price of one).</p><p><br></p><p>Articles discussed in this episode. Subscription may be required</p><ul><li>Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). <a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637956\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637956</a></li><li>Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies</li><li><a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637959\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637959</a></li><li>Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial <a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637966\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637966</a></li></ul><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>www.inquisitiveonc.com</strong></a></p><p>Please find us on Twitter @InquisitiveOnc!</p><p>If you want us to look at a specific trial or subject, email us at<strong> </strong><a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>inquisitiveonc@gmail.com</strong></a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/</p><p><br></p><p><strong>Disclaimer:</strong> This podcast is for educational purposes only. If you are unwell, seek medical advice.</p>","author_name":"Michael Fernando and Josh Hurwitz"}